PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 9 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received notifications of shareholdings from FMR LLC on 6 and 7 March 2018.

On 6 March 2018, FMR LLC (taking into account the holdings of its subsidiary undertakings) has notified Ablynx that it has downward crossed the 5% threshold of total voting rights of Ablynx since 1 March 2018.

On 7 March 2018, FMR LLC (taking into account the holdings of its subsidiary undertakings) has notified Ablynx that it has first downward crossed and then upward crossed the 3% threshold of voting rights (excluding the ones held through financial instruments) on respectively 5 and 6 March 2018.

FMR LLC now holds a total of 2,780,276 voting securities of Ablynx since 6 March 2018, representing 3.70% of the current 75,073,886 outstanding voting rights of Ablynx (versus 5.92% notified previously on 8 February 2018).

The latest notification contains the following information:

• Reason for the notification: acquisition or disposal of voting securities or voting rights
• Notification by: a parent undertaking or a controlling person
• Persons subject to the notification requirement: FMR LLC
• Transaction date: 6 March 2018
• Threshold that is crossed:  5%
• Denominator: 75,073,886
• Details of the notification:

* Type of financial instrument: "Right of Recall"
             

• Chain of controlled undertakings through which the holding is effectively being held: The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.

More information is available in the transparency notifications. A full version of the transparency notifications is available on Ablynx website, under the section Investors.

The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  [email protected]

Lies Vanneste
Director Investor Relations
t:   +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e:  [email protected]

Follow us on Twitter @AblynxABLX

Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t:  +44 (0)20 3709 5700
e:  [email protected]

Joele Frank, Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t:  +1 212-355-4449

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/314ed48d-abc9-4013-90f6-23b70b56d757